Wednesday, July 8, 2026

pharma · Cystic Fibrosis · Rheumatoid Arthritis · LKFT

Lakefront Biotherapeutics NV

Lakefront Biotherapeutics NV clinical programs — 6 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Yalelaan 60, 5th floor, Utrecht 3584 CM, NL HQ
2016 Founded
9 Employees
Public company Type
LKFT · NYSE Ticker
Company details
Status
Public
HQ
Yalelaan 60, 5th floor, Utrecht 3584 CM, NL
Founded
2016
Employees
9
Programs
99
Drugs
26
Patents
0
Intelligence · Clinical Programs

Lakefront Biotherapeutics NV projects

6 ClinicalTrials.gov programs sponsored by Lakefront Biotherapeutics NV.

Lakefront Biotherapeutics NV has 6 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Filgotinib

    Lakefront Biotherapeutics NV

    Ankylosing Spondylitis

    phase 3 small molecule terminated

    3 trials
  2. Filgotinib

    Lakefront Biotherapeutics NV

    Crohn's Disease

    phase 3 small molecule completed

    2 trials
  3. Filgotinib

    Lakefront Biotherapeutics NV

    Psoriatic Arthritis

    phase 3 small molecule terminated

    4 trials
  4. Filgotinib

    Lakefront Biotherapeutics NV

    Ulcerative Colitis

    phase 3 small molecule completed

    2 trials
  5. GLPG CAR T-cell therapy

    Lakefront Biotherapeutics NV

    Hematological Malignancies

    phase 3 gene therapy active

    1 trial
  6. GLPG1690

    Lakefront Biotherapeutics NV

    Idiopathic Pulmonary Fibrosis

    phase 3 small molecule terminated

    2 trials

Frequently asked questions

How many clinical projects does Lakefront Biotherapeutics NV have?

6 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.